Technology at Work
Read along for some updates about cutting-edge technology in rare liver disease that should improve prompt diagnosis, ongoing feedback, and effective interventions.
GLI Leads Charge for Common-Sense Policies to Advance High Quality Care for Everyone
In July, GLI used its voice to challenge policymakers to take steps to advance high quality, equitable care for everyone.
Striving For a Better Future in Cancer
Welcome back to Liver Cancers News – where we keep you up-to-date on what’s happening in the liver cancer world.
GLI and Others Nominate Julius M. Wilder MD, PhD to National Diabetes and Digestive and Kidney Diseases Advisory Council (NDDKAC)
Global Liver Institute is pleased to nominate Julius M. Wilder MD, PhD to be a member of the NIDDK’s National Diabetes and Digestive and Kidney Diseases Advisory Council (NDDKAC).
GLI Urges Passage of the Treat and Reduce Obesity Act (TROA)
Global Liver Institute recognizes the relationship between nonalcoholic fatty liver disease (NAFLD), its advanced form, nonalcoholic steatohepatitis (NASH), and obesity. Preventing liver disease is directly associated with treating and reducing obesity. Worldwide, NASH affects more than 148 million people and continues to become more prevalent each year.